keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis, ustekinumab, biologics

keyword
https://www.readbyqxmd.com/read/28092212/systemic-medications-used-in-treatment-of-common-dermatological-conditions-safety-profile-with-respect-to-pregnancy-breast-feeding-and-content-in-seminal-fluid
#1
S M Brown, K A Aljefri, R Waas, P J Hampton
: Prescribing for pregnant or lactating patients and male patients wishing to father children can be a difficult area for dermatologists. There is a lack of review articles of commonly used systemic medications in dermatology with respect to their effects on developing embryogenesis and their potential transfer across the placenta, in breast milk and in seminal fluid. This paper aims to provide an up to date summary of evidence to better equip dermatologists to inform patients about the effects of systemic medications commonly used in dermatology to treat conditions such as atopic dermatitis, psoriasis and acne, on current and future embryogenesis and fertility...
January 16, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28071837/use-of-tnf-inhibitors-and-ustekinumab-for-psoriasis-during-pregnancy-a-patient-series
#2
Tamara Lund, Simon Francis Thomsen
From 2002 to 2016 a total of seven women with severe refractory psoriasis were exposed to the TNF-inhibitors infliximab and adalimumab or to the IL12/23 inhibitor ustekinumab during one or more pregnancies. Maternal, fetal or teratogenic toxicity were not detected during pregnancy and puerperium. All pregnancies were uneventful and resulted in delivery of 10 healthy children in total, one of the women is due February 2017. Postpartum, five of the women were lactating, but none of the women or newborns developed adverse reactions...
January 10, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28042732/the-potential-utility-of-tildrakizumab-an-interleukin-23-inhibitor-for-the-treatment-of-psoriasis
#3
Zenas Z N Yiu, Richard B Warren
The approved biologic therapies are effective for the treatment of psoriasis, but have limitations. Tildrakizumab has a different mechanism of action and is a humanized immunoglobulin G1κ that binds to the p19 subunit of IL23. Areas covered: Phase I, II and III clinical trials investigated the pharmacokinetics, efficacy, safety and immunogenicity of tildrakizumab for patients with psoriasis. The mean half-life of tildrakizumab is between 20.2 to 28.2 days. Tildrakizumab achieved a PASI 75 of 66% and 74% at week 16 for the doses of 100 mg and 200 mg respectively in a phase IIb randomised clinical trial (RCT), and PASI 75 of 61%/64% and 62%/66% at week 12 for 100 mg and 200 mg respectively in two phase III RCTs...
January 1, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28042711/the-impact-of-pasi-75-and-pasi-90-on-quality-of-life-in-moderate-to-severe-psoriasis-patients
#4
Michael Abrouk, M Nakamura, T H Zhu, B Farahnik, J Koo, T Bhutani
BACKGROUND: It is well known that psoriasis significantly impacts patients' quality of life (QoL). With the introduction of improved treatment modalities with biologic agents, more patients with moderate to severe psoriasis are able to achieve better results as measured by the Psoriasis Area and Severity Index (PASI). PASI 75 indicates a 75% or greater reduction in PASI scores from baseline and is indicative of excellent disease improvement. With newer biologic agents such as secukinumab, ixekizumab and brodalumab, patients are now capable of achieving PASI 90, introducing additional clinical decisions for physicians when considering treatment options...
December 31, 2016: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28038888/biologic-drug-survival-in-israeli-psoriasis-patients
#5
Guy Shalom, Arnon D Cohen, Michael Ziv, Cohen Barak Eran, Ilan Feldhamer, Tamar Freud, Eitan Berman, Shirley Oren, Emmilia Hodak, Lev Pavlovsky
BACKGROUND: Drug survival is defined as the time period of treatment with a certain drug until its cessation. The role of previous exposure to traditional systemic treatments in biologic survival is still unknown. OBJECTIVE: To investigate the drug survival rates of biologic treatments in patients with psoriasis and to identify predictor factors. METHODS: Survival analysis was performed on patients with severe psoriasis who received adalimumab, infliximab, etanercept, and ustekinumab for treatment of psoriasis, drawn from the Clalit Health Services database...
December 28, 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28026823/anti%C3%A2-cytokine-therapy-for-psoriasis-not-only-tnf%C3%A2-%C3%AE-blockers-overview-of-reports-on-the-effectiveness-of-therapy-with-il%C3%A2-12-il%C3%A2-23-and-t-and-b-lymphocyte-inhibitors
#6
Dominika Wcisło-Dziadecka, Martyna Zbiciak, Ligia Brzezińska-Wcisło, Urszula Mazurek
TNF‑α inhibitors - infliximab, etanercept and adalimumab - can be used in the treatment of psoriasis vulgaris and psoriatic arthritis, along with other inhibitors of proinflammatory cytokines, such as interleukin‑12 (IL‑12) and IL‑23. This paper presents the results of research on the use of biological drugs other than the tumor necrosis factor blockers (TNF‑α), namely inhibitors of IL‑12 and IL‑23 (ustekinumab), T‑cell inhibitors (alefacept and efalizumab), B‑cell inhibitors (rituximab), anti‑IL‑17 agents (secukinumab, ixekizumab, and brodalumab) and IL23p19 inhibitors (guselkumab and tildrakizumab)...
December 8, 2016: Postȩpy Higieny i Medycyny Doświadczalnej
https://www.readbyqxmd.com/read/27976465/determination-of-the-nail-psoriasis-severity-index-improvement-rate-standards-for-nail-psoriasis-treatment-in-a-phase-iv-clinical-trial-of-ustekinumab-the-marcopolo-study
#7
LETTER
S W Youn, B R Kim, S Cho, S J Seo, E S Lee, J Y Roh, G S Choi, M G Lee
No abstract text is available yet for this article.
December 15, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27879076/drug-survival-rates-and-reasons-for-drug-discontinuation-in-psoriasis
#8
Tobias Arnold, Marthe-Lisa Schaarschmidt, Raphael Herr, Joachim E Fischer, Sergij Goerdt, Wiebke K Peitsch
BACKGROUND AND OBJECTIVES: Moderate-to-severe psoriasis frequently requires long-term systemic therapy. Reflecting efficacy, safety, and treatment satisfaction, drug survival is an indicator of therapeutic success. The objective of the present study was to assess drug survival rates and reasons for discontinuation of fumaric acid esters (FAE), methotrexate (MTX), acitretin (ACI), cyclosporine A (CyA), adalimumab (ADA), etanercept (ETA), infliximab (INF), and ustekinumab (UST) in patients with moderate-to-severe psoriasis...
November 2016: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/27864841/clinical-factors-predicting-the-therapeutic-response-to-ustekinumab-in-patients-with-moderate-to-severe-chronic-plaque-psoriasis
#9
Young Ji Hwang, Sang Woong Youn, Bo Ri Kim, Dae Young Yu, Youngdoe Kim, Antonio Pires, Soyun Cho, Seong Jun Seo, Eun So Lee, Joo Young Roh, Gwang Seong Choi, Min Geol Lee
While ustekinumab has been widely used as an effective biologic for the treatment of chronic plaque psoriasis, no prospective studies have specifically investigated the clinical factors that may influence treatment outcomes with ustekinumab. This post-hoc analysis aimed to identify specific clinical factors that may influence treatment outcomes with ustekinumab in psoriasis patients. In the MARCOPOLO study, 102 Korean patients with moderate to severe psoriasis were analyzed to assess the influence of baseline characteristics as clinical factors on clinical response (improvement in Psoriasis Area and Severity Index by ≥75%/90% [PASI75/PASI90]) to ustekinumab...
November 18, 2016: Journal of Dermatology
https://www.readbyqxmd.com/read/27858976/survival-rates-of-biological-therapies-for-psoriasis-treatment-in-real-world-clinical-practice-a-canadian-multicentre-retrospective-study
#10
Joseph Ec Marinas, Whan B Kim, Ali Shahbaz, Judy K Qiang, Simon Greaves, Jensen Yeung
BACKGROUND/OBJECTIVES: Data on biologic drug survival in real-world psoriasis treatment are limited. There is a need to evaluate long-term trends of biologic use outside the realm of clinical trials. METHODS: A multicentre chart review was conducted with patients' data from September 2005 to September 2014. Kaplan-Meier plot analysis was used to determine 5-year drug survival rates. A log-rank test was used to compare the rates of drug survival between the studied biologics...
November 12, 2016: Australasian Journal of Dermatology
https://www.readbyqxmd.com/read/27845513/the-switching-from-a-biological-therapy-to-another-biologic-agent-in-psoriatic-patients-the-experience-of-psomarche-group
#11
Giulia Ganzetti, Anna Campanati, Alberta Bettacchi, Giuliano Brandozzi, Valerio Brisigotti, Leonardo Bugatti, Ivana Cataldi, Giorgio Filosa, Alfredo Giacchetti, Giuseppe Lemme, Lorenzo Morresi, Massimiliano Nicolini, Valentina Postacchini, Giuseppe Ricotti, Laura Rosa, Marco Simonacci, Annamaria Offidani
BACKGROUND: Switching is a "hot" topic and the main reasons for switching prior biologic agent are for a primary failure, a secondary failure or drug intolerance, patient's dissatisfaction, physician decision. The aim of the study was to assess the optimization of the switching from a biological to another. METHODS: Five Dermatological Units have participated to PsOMarche working group have studied thirty-eight patients affected moderate to severe chronic plaque psoriasis at time 0 (patient recruitment at time of switching from biological therapy to another), 8 weeks (T8), 16 weeks (T16)...
November 15, 2016: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/27836567/management-of-psoriatic-arthritis-early-diagnosis-monitoring-of-disease-severity-and-cutting-edge-therapies
#12
REVIEW
Siba P Raychaudhuri, Reason Wilken, Andrea C Sukhov, Smriti K Raychaudhuri, Emanual Maverakis
Psoriatic arthritis (PsA) is a heterogeneous disease that can involve a variety of distinct anatomical sites including a patient's peripheral and axial joints, entheses, skin and nails. Appropriate management of PsA requires early diagnosis, monitoring of disease activity, and utilization of cutting edge therapies. To accomplish the former there are a variety of PsA-specific tools available to screen, diagnose, and assess patients. This review will outline the recently developed PsA screening tools, including the Toronto Psoriatic Arthritis Screening Questionnaire (TOPAS), the Psoriasis Epidemiology Screening Tool (PEST), the Psoriatic Arthritis Screening and Evaluation (PASE), and the Psoriasis and Arthritis Screening Questionnaire (PASQ)...
January 2017: Journal of Autoimmunity
https://www.readbyqxmd.com/read/27829672/management-of-psoriatic-arthritis-in-2016-a-comparison-of-eular-and-grappa-recommendations
#13
REVIEW
Laure Gossec, Laura C Coates, Maarten de Wit, Arthur Kavanaugh, Sofia Ramiro, Philip J Mease, Christopher T Ritchlin, Désirée van der Heijde, Josef S Smolen
Psoriatic arthritis (PsA) is a heterogeneous, potentially severe disease. Many therapeutic agents are now available for PsA, but treatment decisions are not always straightforward. To assist in this decision making, two sets of recommendations for the management of PsA were published in 2016 by international organizations - the European League Against Rheumatism (EULAR) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). In both sets of recommendations, the heterogeneity of PsA is recognized and the place of various drugs in the therapeutic armamentarium is discussed...
December 2016: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/27817126/treatment-with-ustekinumab-in-a-spanish-cohort-of-patients-with-psoriasis-and-psoriatic-arthritis-in-daily-clinical-practice
#14
Miriam Almirall, Jesús Rodriguez, Lourdes Mateo, José Manuel Carrascosa, Jaime Notario, Fernando Gallardo
After approval of the use of ustekinumab for treatment of moderate to severe psoriasis, patients with psoriatic arthritis have treated with this drug in daily clinical practice. The aims of this study were to describe baseline characteristics and evolution of a cohort of patients with psoriasis and psoriatic arthritis treated with ustekinumab and to compare differences between patients who discontinued treatment and those who maintained. A retrospective multicenter observational study including patients who had received ustekinumab for a minimum of 3 months from 2009 to 2015 was performed...
November 5, 2016: Clinical Rheumatology
https://www.readbyqxmd.com/read/27785085/treatment-challenges-in-the-management-of-moderate-to-severe-plaque-psoriasis-role-of-secukinumab
#15
REVIEW
Mona Malakouti, Sharon E Jacob, Nancy J Anderson
Psoriasis is a chronic inflammatory skin disease that has a negative impact on psychosocial well-being and cardiometabolic health. Treatment options for moderate-to-severe psoriasis have expanded with the development of interleukin-17 (IL-17) inhibitors, the first of which is now available - secukinumab. Secukinumab is a fully human monoclonal immunoglobulin G1 κ antibody that selectively inhibits the ligand IL-17A. In head-to-head studies, it is more effective than etanercept and ustekinumab, particularly in achieving Psoriasis Area and Severity Index (PASI) 90/100 and achieving PASI 50/75 as early as week 4...
2016: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/27783534/healthcare-resource-utilization-healthcare-costs-and-dose-escalation-in-psoriasis-patients-initiated-on-ustekinumab-versus-adalimumab-a-retrospective-claim-study
#16
Jashin J Wu, Annie Guérin, Geneviève Gauthier, Murali Sundaram
BACKGROUND: Adalimumab and ustekinumab are effective psoriasis treatments. This study compares healthcare resource utilization (HRU), costs and dose escalation and describes starting dose trends in ustekinumab versus adalimumab psoriasis patients. METHODS: Adult psoriasis patients initiating adalimumab/ustekinumab on/after 25 September 2009 were selected from a US claims database and classified into biologic-naïve and biologic-experienced samples. RESULTS: A total of 602 ustekinumab and 3470 adalimumab biologic-naïve and 1193 ustekinumab and 1467 adalimumab biologic-experienced patients were included...
November 15, 2016: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/27771122/-vaccination-status-in-psoriasis-patients-on-immunosuppressant-therapy-including-biologics
#17
A Bonhomme, E Fréling, M Reigneau, C Poreaux, A Valois, F Truchetet, A Barbaud, J-L Schmutz
OBJECTIVES: To evaluate the vaccine coverage of psoriasis patients prior to initiating or changing immunosuppressant therapy, and to verify that the prescribed vaccines have been administered. PATIENTS AND METHODS: We conducted a bi-centre, observational, cross-sectional study over 9 months. Psoriasis patients in whom immunosuppressant therapy (comprising cyclosporine, methotrexate, etanercept, infliximab, adalimumab or ustekinumab) was indicated were included. Medical history, previous treatments, vaccination status, viral serology results (for hepatitis B, measles, and chickenpox), and reasons for non-vaccination were assessed via questionnaire...
October 19, 2016: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/27765025/staphylococcus-aureus-bacteremia-with-iliac-artery-endarteritis-in-a-patient-receiving-ustekinumab
#18
Insa Joost, Johannes Steinfurt, Philipp T Meyer, Winfried V Kern, Siegbert Rieg
BACKGROUND: Ustekinumab (Stelara®), a human monoclonal antibody targeting the p40-subunit of interleukin (IL)-12 and IL-23, is indicated for moderate to severe plaque psoriasis and psoriatic arthritis. In large multicenter, prospective trials assessing efficacy and safety of ustekinumab increased rates of severe infections have not been observed so far. CASE PRESENTATION: Here, we report the case of a 64-year old woman presenting with chills, pain and swelling of her right foot with dark maculae at the sole, and elevated inflammatory markers...
October 20, 2016: BMC Infectious Diseases
https://www.readbyqxmd.com/read/27757919/comparing-biologic-cost-per-treated-patient-across-indications-among-adult-us-managed-care-patients-a-retrospective-cohort-study
#19
Tao Gu, Neel Shah, Gaurav Deshpande, Derek H Tang, Debra F Eisenberg
BACKGROUND: The relative cost of biologics in the treatment of autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, psoriasis, and ankylosing spondylitis, is a key consideration for managed care payers. OBJECTIVES: Our objective was to estimate biologic costs and treatment patterns in US managed care patients with rheumatoid arthritis, psoriatic arthritis, psoriasis, and/or ankylosing spondylitis. METHODS: This retrospective study used administrative claims data from the HealthCore Integrated Research Database (HIRD(SM)) for adults with rheumatoid arthritis, psoriatic arthritis, psoriasis, and/or ankylosing spondylitis who received abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab, tocilizumab, or ustekinumab between 1 July 2009 and 31 January 2013...
December 2016: Drugs—Real World Outcomes
https://www.readbyqxmd.com/read/27749221/paradoxical-onset-of-psoriatic-arthritis-during-treatment-with-biologic-agents-for-plaque-psoriasis-a-combined-dermatology-and-rheumatology-clinical-study
#20
Maddalena Napolitano, Nicola Balato, Francesco Caso, Luisa Costa, Matteo Megna, Teresa Cirillo, Anna Balato, Raffaele Scarpa
OBJECTIVES: To evaluate the incidence of new cases of psoriatic arthritis (PsA) in patients with plaque psoriasis receiving biologic drugs. METHODS: A retrospective study was performed on 434 psoriatic patients under biologic treatment, attending the Psoriasis Care Centre of Dermatology at the University Federico II of Naples from January 2011 to November 2015. As part of the routine clinical practice, assessment of disease activity was made at baseline, and every 3 months...
September 8, 2016: Clinical and Experimental Rheumatology
keyword
keyword
77975
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"